{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:08:56Z","timestamp":1755598136797,"version":"3.41.0"},"reference-count":35,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,5,28]]},"DOI":"10.1248\/bpb.b25-00083","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T22:07:19Z","timestamp":1748383639000},"page":"713-720","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the Effect of Aldehyde Oxidase Inhibitors on 6-Mercaptopurine Metabolism"],"prefix":"10.1248","volume":"48","author":[{"given":"Hinata","family":"Ueda","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-7041","authenticated-orcid":false,"given":"Katsuya","family":"Narumi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"},{"name":"Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Furugen","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15\u20134\u20131 Maeda 7, Teine-ku, Sapporo 006\u20138585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-2391","authenticated-orcid":false,"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"},{"name":"Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, Moser G. Azathioprine treatment and male fertility in inflammatory bowel disease. <i>Gastroenterology<\/i>, <b>121<\/b>, 1048\u20131053 (2001).","DOI":"10.1053\/gast.2001.28692"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. <i>Mol. Pharmacol.<\/i>, <b>70<\/b>, 747\u2013754 (2006).","DOI":"10.1124\/mol.106.025288"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Teich N, Mohl W, Bokemeyer B, B\u00fcndgens B, B\u00fcning J, Miehlke S, H\u00fcppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weism\u00fcller J, Drabik A, Stallmach A. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases\u2014a prospective study on incidence and severity. <i>J. Crohns Colitis<\/i>, <b>10<\/b>, 61\u201368 (2016).","DOI":"10.1093\/ecco-jcc\/jjv188"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. <i>Aliment. Pharmacol. Ther.<\/i>, <b>24<\/b>, 331\u2013342 (2006).","DOI":"10.1111\/j.1365-2036.2006.02977.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Th\u00e9or\u00eat Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. <i>Gastroenterology<\/i>, <b>118<\/b>, 705\u2013713 (2000).","DOI":"10.1016\/S0016-5085(00)70140-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. <i>Eur. J. Gastroenterol. Hepatol.<\/i>, <b>20<\/b>, 1238\u20131242 (2008).","DOI":"10.1097\/MEG.0b013e3282ffda37"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? <i>Pharmacogenomics<\/i>, <b>11<\/b>, 177\u2013188 (2010).","DOI":"10.2217\/pgs.09.155"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, Haritunians T, Ye BD, Kim KJ, Park SH, Park SK, Yang DH, Dubinsky M, Lee I, McGovern DP, Liu J, Song K. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. <i>Nat. Genet.<\/i>, <b>46<\/b>, 1017\u20131020 (2014).","DOI":"10.1038\/ng.3060"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Broekman MM, Roelofs HM, Wong DR, Kerstholt M, Leijten A, Hoentjen F, Peters WH, Wanten GJ, de Jong DJ. Allopurinol and 5-aminosalicylic acid influence thiopurine-induced hepatotoxicity <i>in vitro<\/i>. <i>Cell Biol. Toxicol.<\/i>, <b>31<\/b>, 161\u2013171 (2015).","DOI":"10.1007\/s10565-015-9301-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Choughule KV, Barnaba C, Joswig-Jones CA, Jones JP. <i>In vitro<\/i> oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase. <i>Drug Metab. Dispos.<\/i>, <b>42<\/b>, 1334\u20131340 (2014).","DOI":"10.1124\/dmd.114.058107"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kurzawski M, Dziewanowski K, Safranow K, Drozdzik M. Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine. <i>Ther. Drug Monit.<\/i>, <b>34<\/b>, 266\u2013274 (2012).","DOI":"10.1097\/FTD.0b013e31824aa681"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A, Duley J, Sanderson JD. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. <i>Aliment. Pharmacol. Ther.<\/i>, <b>30<\/b>, 375\u2013384 (2009).","DOI":"10.1111\/j.1365-2036.2009.04057.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ueda H, Narumi K, Asano S, Saito Y, Furugen A, Kobayashi M. Comparative study on the occurrence of adverse effects in the concomitant use of azathioprine and aldehyde oxidase inhibitors. <i>Expert Opin. Drug Saf.<\/i>, <b>23<\/b>, 89\u201397 (2024).","DOI":"10.1080\/14740338.2023.2295976"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kudo M, Sasaki T, Ishikawa M, Hirasawa N, Hiratsuka M. Kinetics of 6-thioxanthine metabolism by allelic variants of xanthine oxidase. <i>Drug Metab. Pharmacokinet.<\/i>, <b>25<\/b>, 361\u2013366 (2010).","DOI":"10.2133\/dmpk.DMPK-10-RG-029"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Itoh K, Masubuchi A, Sasaki T, Adachi M, Watanabe N, Nagata K, Yamazoe Y, Hiratsuka M, Mizugaki M, Tanaka Y. Genetic polymorphism of aldehyde oxidase in Donryu rats. <i>Drug Metab. Dispos.<\/i>, <b>35<\/b>, 734\u2013739 (2007).","DOI":"10.1124\/dmd.106.011502"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by 239 drugs. <i>J. Clin. Pharmacol.<\/i>, <b>44<\/b>, 7\u201319 (2004).","DOI":"10.1177\/0091270003260336"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Takaoka N, Sanoh S, Okuda K, Kotake Y, Sugahara G, Yanagi A, Ishida Y, Tateno C, Tayama Y, Sugihara K, Kitamura S, Kurosaki M, Terao M, Garattini E, Ohta S. Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug\u2013drug interactions. <i>Biochem. Pharmacol.<\/i>, <b>154<\/b>, 28\u201338 (2018).","DOI":"10.1016\/j.bcp.2018.04.017"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Barr JT, Jones JP. Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. <i>Drug Metab. Dispos.<\/i>, <b>41<\/b>, 24\u201329 (2013).","DOI":"10.1124\/dmd.112.048546"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Elion GB. Significance of azathioprine metabolites. <i>Proc. R. Soc. Med.<\/i>, <b>65<\/b>, 257\u2013260 (1972).","DOI":"10.1177\/003591577206500315"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Gardiner SJ, Gearry RB, Burt MJ, Chalmers-Watson T, Chapman BA, Ross AG, Stedman CA, Huelsen A, Barclay ML. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. <i>J. Gastroenterol. Hepatol.<\/i>, <b>26<\/b>, 49\u201354 (2011).","DOI":"10.1111\/j.1440-1746.2010.06489.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gawlik-Dziki U, Dziki D, \u015awieca M, Nowak R. Mechanism of action and interactions between xanthine oxidase inhibitors derived from natural sources of chlorogenic and ferulic acids. <i>Food Chem.<\/i>, <b>225<\/b>, 138\u2013145 (2017).","DOI":"10.1016\/j.foodchem.2017.01.016"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Shi YW, Wang CP, Liu L, Liu YL, Wang X, Hong Y, Li Z, Kong LD. Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. <i>Mol. Nutr. Food Res.<\/i>, <b>56<\/b>, 1433\u20131444 (2012).","DOI":"10.1002\/mnfr.201100828"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kudo M, Moteki T, Sasaki T, Konno Y, Ujiie S, Onose A, Mizugaki M, Ishikawa M, Hiratsuka M. Functional characterization of human xanthine oxidase allelic variants. <i>Pharmacogenet. Genomics<\/i>, <b>18<\/b>, 243\u2013251 (2008).","DOI":"10.1097\/FPC.0b013e3282f55e2e"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hall WW, Krenitsky TA. Aldehyde oxidase from rabbit liver: specificity toward purines and their analogs. <i>Arch. Biochem. Biophys.<\/i>, <b>251<\/b>, 36\u201346 (1986).","DOI":"10.1016\/0003-9861(86)90048-2"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Rashidi MR, Beedham C, Smith JS, Davaran S. <i>In vitro<\/i> study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. <i>Drug Metab. Pharmacokinet.<\/i>, <b>22<\/b>, 299\u2013306 (2007).","DOI":"10.2133\/dmpk.22.299"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Terao M, Garattini E, Rom\u00e3o MJ, Leimk\u00fchler S. Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes. <i>J. Biol. Chem.<\/i>, <b>295<\/b>, 5377\u20135389 (2020).","DOI":"10.1074\/jbc.REV119.007741"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Basit A, Fan PW, Khojasteh SC, Murray BP, Smith BJ, Heyward S, Prasad B. Comparison of tissue abundance of non-cytochrome P450 drug-metabolizing enzymes by quantitative proteomics between humans and laboratory animal species. <i>Drug Metab. Dispos.<\/i>, <b>50<\/b>, 197\u2013203 (2022).","DOI":"10.1124\/dmd.121.000774"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hanioka N, Saito K, Isobe T, Ohkawara S, Jinno H, Tanaka-Kagawa T. Favipiravir biotransformation in liver cytosol: species and sex differences in humans, monkeys, rats, and mice. <i>Biopharm. Drug Dispos.<\/i>, <b>42<\/b>, 218\u2013225 (2021).","DOI":"10.1002\/bdd.2275"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Uehara S, Yoneda N, Higuchi Y, Yamazaki H, Suemizu H. Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. <i>Drug Metab. Pharmacokinet.<\/i>, <b>41<\/b>, 100419 (2021).","DOI":"10.1016\/j.dmpk.2021.100419"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Crouch RD, Blobaum AL, Felts AS, Conn PJ, Lindsley CW. Species-specific involvement of aldehyde oxidase and xanthine oxidase in the metabolism of the pyrimidine-containing mGlu<sub>5<\/sub>-negative allosteric modulator VU0424238 (Auglurant). <i>Drug Metab. Dispos.<\/i>, <b>45<\/b>, 1245\u20131259 (2017).","DOI":"10.1124\/dmd.117.077552"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T. Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. <i>Drug Metab. Dispos.<\/i>, <b>32<\/b>, 479\u2013483 (2004).","DOI":"10.1124\/dmd.32.5.479"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ban H, Andoh A, Imaeda H, Kobori A, Bamba S, Tsujikawa T, Sasaki M, Saito Y, Fujiyama Y. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. <i>J. Gastroenterol.<\/i>, <b>45<\/b>, 1014\u20131021 (2010).","DOI":"10.1007\/s00535-010-0248-y"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Jelovac M, Kotur N, Ristivojevic B, Pavlovic D, Spasovski V, Damjanov N, Pavlovic S, Zukic B. Can pharmacogenetic variants in TPMT, MTHFR and SLCO1B1 genes be used as potential markers of outcome prediction in systemic sclerosis patients? <i>Int. J. Mol. Sci.<\/i>, <b>24<\/b>, 8538 (2023).","DOI":"10.3390\/ijms24108538"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Cao H, Pauff JM, Hille R. Substrate orientation and catalytic specificity in the action of xanthine oxidase: the sequential hydroxylation of hypoxanthine to uric acid. <i>J. Biol. Chem.<\/i>, <b>285<\/b>, 28044\u201328053 (2010).","DOI":"10.1074\/jbc.M110.128561"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Rowland K, Lennard L, Lilleyman JS. <i>In vitro<\/i> metabolism of 6-mercaptopurine by human liver cytosol. <i>Xenobiotica<\/i>, <b>29<\/b>, 615\u2013628 (1999).","DOI":"10.1080\/004982599238434"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b25-00083\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T03:33:55Z","timestamp":1748662435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b25-00083\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00083","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"article-number":"b25-00083"}}